Endocrine Comorbidities in Fibromyalgia
Clinical Endocrinology · 2025
DOI: 10.1111/cen.70063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Eli Magen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Leumit Health Services, Tel Aviv - Jaffa, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Fibromyalgia, Endocrine System Diseases. Die Arbeit nennt 47 Literaturangaben.
Abstract (Originalsprache)
Background
Fibromyalgia (FM) is a chronic pain syndrome increasingly linked to immune and endocrine dysfunction. This study aimed to evaluate the prevalence of endocrine comorbidities in FM patients compared to matched controls using a large healthcare database.
Methods
A population‐based case‐control study was conducted using data from Leumit Health Services, Israel. The cohort included 9,232 adults diagnosed with FM according to ACR criteria, matched by age and sex to 46,160 control subjects. Endocrine disorders were identified via ICD‐9 codes. Statistical analyses included Student's t ‐test or Mann–Whitney U test for continuous variables, Pearson's chi‐squared or Fisher's exact test for categorical variables, and multivariable logistic regression adjusting for age, sex, and BMI. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Both statistical significance and effect sizes are reported to facilitate assessment of clinical relevance.
Results
FM patients showed a significantly higher prevalence of endocrine comorbidities compared to controls. Thyroid disorders, including Hashimoto's thyroiditis (13.3% vs. 10.0%; OR = 1.38, p < 0.001) and Graves' disease (4.1% vs. 3.0%; OR = 1.38, p < 0.001), were more common. Diabetes mellitus type 1 (0.9% vs. 0.3%; OR = 3.64, p < 0.001) and type 2 (23.5% vs. 18.6%; OR = 1.34, p < 0.001), adrenal disorders such as Cushing's syndrome (OR = 5.01, p < 0.001), prolactinoma (OR = 1.81, p = 0.014), osteoporosis (19.1% vs. 11.6%; OR = 1.80, p < 0.001), and vitamin D deficiency (39.9% vs. 30.3%; OR = 1.53, p < 0.001) were also significantly associated. Less common conditions (e.g., thyroiditis subtypes and thyroid malignancy) also appeared more frequent among FM patients, though effect sizes varied and some associations did not reach robust significance.
Conclusion
This is among the largest datasets to date to systematically examine a comprehensive spectrum of endocrine comorbidities in FM. Our findings suggest that FM and endocrine disorders may share overlapping pathophysiological mechanisms. Future studies should clarify causal pathways and assess the clinical utility of routine endocrine screening in FM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Leumit Health Services, Tel Aviv - Jaffa, Tel Aviv, Israel.
- Medicine A Department, Assuta Ashdod University Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel.
- Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
- Endocrinology Unit, Assuta Ashdod University Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel.
- Rheumatology Unit, Assuta Ashdod University Medical Center, Ben-Gurion University of the Negev, Beer Sheva, Israel.
- Adelson School of Medicine, Ariel University, Ariel, Israel.
ORCID-Profile: Eli Magen
Zitieren
APA
Magen, E., Tolkin, L., Aamar, S., Magen, I., Merzon, E., Green, I., Golan-Cohen, A., Vinker, S., & Israel, A. (2025). Endocrine Comorbidities in Fibromyalgia. Clinical Endocrinology. https://doi.org/10.1111/cen.70063
Vancouver
Magen E, Tolkin L, Aamar S, Magen I, Merzon E, Green I, et al. Endocrine Comorbidities in Fibromyalgia. Clinical Endocrinology. 2025. doi:10.1111/cen.70063
BibTeX
@article{Magen2025,
author = {Magen, Eli and Tolkin, Lior and Aamar, Suhail and Magen, Israel and Merzon, Eugene and Green, Ilan and Golan-Cohen, Avivit and Vinker, Shlomo and Israel, Ariel},
title = {Endocrine Comorbidities in Fibromyalgia},
journal = {Clinical Endocrinology},
year = {2025},
doi = {10.1111/cen.70063}
}
EUVIMED